Targets › GLP1R
77 programs from 60 companies in 620 trials: 186 Phase 2, 174 Phase 3, 136 Phase 1, 124 Phase 4; Metabolic and endocrine, Cardiovascular, Immunology; next expected readout Nov 2026.
G protein-coupled receptor for glucagon-like peptide 1 (GLP-1). Ligand binding triggers activation of a signaling cascade that leads to the activation of adenylyl cyclase and increased intracellular cAMP levels. (UniProt, P43220)
Open in Phaseline: the race on GLP1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Mayo Clinic | BCG Solution Glucagon-like peptide 1 receptor agonist | GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274 | Phase 4 | Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss … | Nov 2026 |
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| Eli Lilly | Tirzepatide (LY3298176) Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist | GIPR, GLP1R | Phase 4 | Diabetes Mellitus, Type 2; Psoriatic Arthritis; Type 2 Diabetes; Psoriasis … | Nov 2026 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Efsubaglutide Alfa Injection GLP-1 receptor agonist | GLP1R | Phase 4 | Obesity | Nov 2026 |
| Novo Nordisk | Semaglutide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 4 | Obesity; Cardiovascular Risk; Cardiovascular Disease; Diabetes Mellitus, Type 2 … | Dec 2026 |
| Children's Hospital Medical Center, Cincinnati | GLP-1 agonist GLP-1 receptor agonist | GLP1R | Phase 4 | Diabetes Mellitus, Type 2 | Dec 2026 |
| Odense University Hospital | Capsule FMT Amiloride-sensitive sodium channel, ENaC blocker | GLP1R, ATP4A, ATP4B, CTLA4, FKBP1A, TNF, PDCD1, SCNN1A, SCNN1B, SCNN1G | Phase 4 | Gastroesophageal Reflux; Colitis; Chronic Kidney Disease(CKD); Postmenopausal Women … | Dec 2026 |
| Maisa N. Feghali, MD | Exenatide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 4 | Gestational Diabetes | Dec 2026 |
| Medical College of Wisconsin | GLP-1 agonists GLP-1 receptor agonist | GLP1R | Phase 4 | Psoriatic Arthritis (PsA) | Oct 2027 |
| China National Center for Cardiovascular Diseases | Mazdutide Dual GLP-1/glucagon receptor agonist | GLP1R, GCGR | Phase 4 | Obesity & Overweight | Dec 2027 |
| Hangzhou Zhongmei Huadong Pharmaceutical | liraglutide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 4 | T2DM (Type 2 Diabetes Mellitus) | Dec 2027 |
| University of Missouri-Columbia | GLP-1 receptor agonist GLP-1 receptor agonist | GLP1R | Phase 4 | Morbid Obesity | Jul 2028 |
| West China Hospital | Mazdutide GLP-1/GCG receptor dual agonist | GLP1R, GCGR | Phase 4 | Metabolic Dysfunction-Associated Steatohepatitis | Feb 2029 |
| Green Valley (Shanghai) Pharmaceuticals | Sodium Oligomannate Capsules (GV-971) Modulator of gut microbiota and neuroinflammation | GLP1R, FFAR2 | Phase 4 | Alzheimer Disease; Alzheimer's Disease | Jun 2029 |
| The Cleveland Clinic | GLP-1 or GIP-based therapy GLP-1 receptor agonist and/or GIP receptor agonist | GLP1R, GIPR | Phase 4 | GLP - 1 | – |
| Gan & Lee Pharmaceuticals. | GZR4 GLP-1 receptor agonist | GLP1R | Phase 3 | Diabetes | Nov 2026 |
| Amgen | Maridebart cafraglutide (AMG 133) GLP-1 receptor agonist and GIP receptor agonist (dual GLP-1/GIP receptor agonist) | GLP1R, GIPR | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight; Obesity; Obesity Disease; Obstructive Sleep Apnea … | Nov 2026 |
| Eli Lilly | Brenipatide (LY3537031) GLP-1 receptor agonist | GLP1R | Phase 3 | Depressive Disorder, Major; Alcohol Use Disorder; Smoking; Irritable Bowel Syndrome … | Nov 2026 |
| Hangzhou Zhongmei Huadong Pharmaceutical | HDM1005 injection GLP-1 receptor agonist | GLP1R | Phase 3 | Obesity & Overweight; Type 2 Diabetes; Obesity; Overweight and/or Obesity | Nov 2026 |
| Eli Lilly | Retatrutide Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist | GCGR, GLP1R, GIPR | Phase 3 | Obesity; Type 2 Diabetes; Diabetes Mellitus, Type 2; Atherosclerotic Cardiovascular Disease (ASCVD) … | Nov 2026 |
| Beijing Dongfang Biotech | JY09 (1.2mg) Exendin-4 Fc fusion protein; GLP-1 receptor agonist | GLP1R | Phase 3 | Type 2 Diabetes Mellitus; Type2 Diabetes Mellitus | Nov 2026 |
| Beijing QL Biopharmaceutical | Zovaglutide (ZT002 Injection) GLP-1 receptor agonist | GLP1R | Phase 3 | Overweight , Obesity; Overweight,Obesity; Overweight, Obesity | Dec 2026 |
| Boehringer Ingelheim | Survodutide Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist | GLP1R, GCGR | Phase 3 | Type 2 Diabetes; Metabolic Dysfunction Associated Steatohepatitis; Metabolic Dysfunction Associated Steatohepatitis (MASH); Healthy … | Dec 2026 |
| Novo Nordisk | Liraglutide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 3 | Obesity; Type 2 Diabetes Patients; Atrial Fibrillation; Severe Obesity … | Dec 2026 |
| Eli Lilly | Eloralintide (LY3841136) GLP-1/GCG dual receptor agonist | GLP1R, GCGR | Phase 3 | Overweight; Obesity; Sleep Apnea, Obstructive; Osteoarthritis … | Dec 2026 |
| Fujian Shengdi Pharmaceutical | HRS9531 Injection GLP-1 receptor agonist | GLP1R | Phase 3 | Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy; Bstructive Sleep Apnea (OSA) and Obesity; Type 2 Diabetes; Obesity … | Dec 2026 |
| Innovent Biologics (Suzhou) | IBI362 GLP-1 receptor agonist | GLP1R | Phase 3 | Overweight; Sleep Apnea; Adolescents With Obesity or Overweight With Weight-Related Comorbidities; Obesity … | Dec 2026 |
| Novo Nordisk | Cagrilintide B Dual GLP-1/glucagon receptor agonist | GLP1R, GCG, CALCR | Phase 3 | Obesity; Overweight; Cardiovascular Disease; Diabetes Mellitus, Type 2 | Jan 2027 |
| Pfizer | Berobenatide (PF-08653944, MET097) Dual GLP-1R/GIPR agonist | GIPR, GLP1R | Phase 3 | Obesity and Overweight; Obesity; Apnea; Overweight … | Jan 2027 |
| Amylyx Pharmaceuticals | Avexitide Glucagon-like peptide 1 receptor antagonist | GLP1R | Phase 3 | Post Bariatric Hypoglycemia | Feb 2027 |
| Eli Lilly | Orforglipron (LY3502970) GLP-1 receptor agonist | GLP1R | Phase 3 | Obesity; Diabetes Mellitus, Type 2; Hypertension; Urinary Incontinence,Stress … | Feb 2027 |
| Hangzhou Sciwind Biosciences | XW003 injection GLP-1 receptor agonist | GLP1R | Phase 3 | OSA - Obstructive Sleep Apnea; Obesity | Feb 2027 |
| Roche | Enicepatide (RO7795068) Dual GLP-1/GIP receptor agonist | GLP1R, GIPR | Phase 3 | Obesity; Obesity or Overweight; Healthy Participants | Apr 2027 |
| Kailera | Ribupatide (KAI-9531) GLP-1 receptor agonist | GLP1R | Phase 3 | Obesity; Obesity With Diabetes; End Stage Renal Disease | May 2027 |
| Viking Therapeutics | VK2735 GLP-1 and GIP dual agonist | GLP1R, GIPR | Phase 3 | Weight Loss; Obese Adults | May 2027 |
| Novo Nordisk | CagriSema Amylin and GLP-1 receptor agonist combination | GLP1R, CALCR | Phase 3 | Obesity; Diabetes Mellitus, Type 2; Overweight | Jun 2027 |
| Chendu DIAO Pharmaceutical Group | DA-302168S GLP-1R agonist | GLP1R | Phase 3 | Overweight and Obesity | Jul 2027 |
| Altimmune | Pemvidutide GLP-1 and glucagon receptor dual agonist | GLP1R, GCGR | Phase 3 | Metabolic Dysfunction-Associated Steatohepatitis (MASH); Alcohol-associated Liver Disease | Sep 2027 |
| Hanmi Pharmaceutical Company | Efpeglenatide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 3 | Type 2 Diabetes | Nov 2027 |
| Eli Lilly | Dulaglutide (LY2189265) Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 3 | Type 2 Diabetes; Myocardial Injury; Cystic Fibrosis; Diabetes Mellitus, Type 1 … | Dec 2027 |
| Hangzhou Sciwind Biosciences | Econoglutide Injection GLP-1 receptor agonist | GLP1R | Phase 3 | Knee Osteoarthritis | May 2028 |
| Novo Nordisk | Zenagamtide GLP-1/GIP receptor agonist | GLP1R, GIPR | Phase 3 | Overweight; Type 2 Diabetes | Jun 2028 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | aleniglipron GLP-1 receptor agonist | GLP1R | Phase 3 | Obesity; Obesity, Overweight, or Chronic Weight Management; Obese | Sep 2028 |
| Roche | Petrelintide Dual GLP-1 and glucagon receptor agonist | GLP1R, GCGR | Phase 3 | Obesity or Overweight | Oct 2028 |
| Fu Jen Catholic University Hospital | GLP-1 receptor agonists (long-acting) GLP-1 receptor agonist | GLP1R | Phase 3 | GLP-1 | Jun 2029 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Mazdutide (IBI362) Triple GLP-1/GIP/glucagon receptor agonist | GLP1R, GIPR, GCGR | Phase 3 | Dementia, Mild | Aug 2029 |
| Seattle Children's Hospital | Exenatide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 3 | Childhood Obesity | – |
| Nanjing First Hospital, Nanjing Medical University | GLP-1RA GLP-1 receptor agonist | GLP1R | Phase 3 | Type 2 Diabetes Mellitus | – |
| Regeneron Pharmaceuticals | Olatorepatide (HS-20094) GLP-1 and GIP receptor agonist | GLP1R, GIPR | Phase 2 | Overweight or Obesity | Nov 2026 |
| Eli Lilly | LY3938577 GLP-1 receptor agonist | GLP1R | Phase 2 | Diabetes Mellitus, Type 2 | Nov 2026 |
| Shanghai Minwei Biotechnology | MWN109 2 GLP-1 receptor agonist | GLP1R | Phase 2 | Overweight , Obesity; Type 2 Diabetes Mellitus (T2DM); Overweight or Obese; Overweight or Obesity | Nov 2026 |
| Roche | RO7795081 GLP-1/GIP receptor dual agonist | GIPR, GLP1R | Phase 2 | Type 2 Diabetes Mellitus; Overweight; Healthy Volunteers; Renal Impairment | Dec 2026 |
| Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | Efsubaglutide Alfa GLP-1 receptor agonist | GLP1R | Phase 2 | Obesity and Overweight; Adolescence Obesity | Dec 2026 |
| AstraZeneca | AZD6234 in combination with AZD9550 Dual GCG and GLP-1 receptor agonist | GCG, GLP1R | Phase 2 | Obesity/Overweight; Healthy Participants; Overweight and Obesity; Hepatic Impairment | Jan 2027 |
| Novartis | JSB462 (luxdegalutamide) GLP-1 receptor agonist | GLP1R | Phase 2 | Prostatic Cancer, Castration-Resistant; Metastatic Hormone-sensitive Prostate Cancer; Metastatic Prostate Cancer (mCRPC); Progressive Metastatic Castrate Resistant Prostate Cancer | Jan 2027 |
| Hudson Biotech | Retatrutide (LY3437943) Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist | GCGR, GLP1R, GIPR | Phase 2 | Obesity | Mar 2027 |
| Sun Pharmaceutical Industries | GL0034 GLP-1 receptor agonist | GLP1R | Phase 2 | Type II Diabetes Mellitus | Apr 2027 |
| Chinese University of Hong Kong | GLP-1 receptor agonist GLP-1 receptor agonist | GLP1R | Phase 2 | Cerebral Small Vessel Disease | May 2027 |
| Shanghai Zhongshan Hospital | HEC88473 GLP-1/FGF21 dual agonist | GLP1R, FGFR1 | Phase 2 | PCOS (Polycystic Ovary Syndrome) | Jun 2027 |
| Hanmi Pharmaceutical Company | HM15912 (sonefpeglutide) GLP-1 receptor agonist | GLP1R | Phase 2 | Short Bowel Syndrome | Dec 2027 |
| Verdiva Bio Dev | VRB-101 (Ecnoglutide) GLP-1 receptor agonist | GLP1R | Phase 2 | Obesity | Mar 2028 |
| University of Virginia | GLP-1 receptor agonist GLP-1 receptor agonist | GLP1R | Phase 2 | Obesity in Children | Feb 2030 |
| University Hospital, Gentofte, Copenhagen | Dapiglutide Dual GLP-1R/GLP-2R agonist | GLP1R, GLP2R | Phase 2 | Obesity | – |
| Durham VA Medical Center | GLP-1 receptor agonist GLP-1 receptor agonist - once weekly injectable; mimics effects of Roux-en-Y gastric bypas | GLP1R | Phase 2 | Type 2 Diabetes | – |
| 4Moving Biotech | Liraglutide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 2 | Knee Osteoarthritis | – |
| Daewoong Pharmaceutical | DWRX5003 GLP-1 receptor agonist delivered via microneedle patch | GLP1R | Phase 1 | Obesity & Overweight | Nov 2026 |
| Merck & Co. (MSD) | MK-4082 GLP-1 receptor agonist | GLP1R | Phase 1 | Healthy | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQF3250 capsules glucagon-like peptide-1 receptor agonist | GLP1R | Phase 1 | Hyperglycemia; Overweight/Obesity; Type 2 Diabetes Mellitus Combined With Overweight or Obesity | Dec 2026 |
| Hangzhou Sciwind Biosciences | ecnoglutide tablets GLP-1 receptor agonist | GLP1R | Phase 1 | Overweight and/or Obesity | Jan 2027 |
| Terrestrial Bio | VX-201 GLP-1 receptor agonist delivered via microneedle array patch | GLP1R | Phase 1 | Overweight and/or Obesity | Feb 2027 |
| Yale University | GLP-1 analogue GLP-1 receptor agonist | GLP1R | Phase 1 | type1diabetes | Aug 2027 |
| David D'Alessio, M.D. | Exendin-9 Competitive antagonist of the GLP-1 receptor | GLP1R | Phase 1 | Diabetes (DM) | Dec 2027 |
| China-Japan Friendship Hospital | GLP-1 Receptor Agonists GLP-1 receptor agonist | GLP1R | Phase 1 | Obesity | Dec 2027 |
| Mapi Pharma | SG Depot 2 mg GLP-1 receptor agonist | GLP1R | Phase 1 | Diabete Type 2 | May 2028 |
| Biolingus | Liraglutide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 1 | Diabete Type 2 | – |
| Shanghai World Leader Pharmaceutical | Semaglutide (WL1006) Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 1 | Overweight | – |
| Shanghai Xitaili Biomedicine Technology | XTL6001 triple-target GLP-1 receptor agonist | GLP1R | Phase 1 | Weight Management in Adult Patients With Obesity or Overweight | – |
Obesity (110) Overweight (26) Diabetes Mellitus, Type 2 (17) Type 2 Diabetes (16) Healthy (9) Obesity or Overweight (6) Type 2 Diabetes Mellitus (6) Obesity and Obesity-related Medical Conditions (6) Alcohol Use Disorder (6) Type 1 Diabetes (6) Obstructive Sleep Apnea (5) Diabetes (5)
protein or peptide (36), small molecule (29), mixed (9)
Eli Lilly (7) Novo Nordisk (5) Roche (3) Hangzhou Sciwind Biosciences (3) The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) Hangzhou Zhongmei Huadong Pharmaceutical (2) Hanmi Pharmaceutical Company (2) AstraZeneca (1) Amgen (1) Regeneron Pharmaceuticals (1) Green Valley (Shanghai) Pharmaceuticals (1) Innovent Biologics (Suzhou) (1) Daewoong Pharmaceutical (1) Fujian Shengdi Pharmaceutical (1) Boehringer Ingelheim (1) Beijing QL Biopharmaceutical (1) Pfizer (1) Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (1) Shanghai Minwei Biotechnology (1) Nanjing First Hospital, Nanjing Medical University (1)
GIPR (12) GCGR (9) GCG (2) CALCR (2) OPRM1 (2) PDCD1 (2) FFAR2 (1) GLP2R (1) FGFR1 (1) SLC5A2 (1) SLC6A2 (1) UNKNOWN (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.